title: Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation.
abstract: Periodontal diseases are comprised of a group of inflammatory conditions that result in the destruction of the supporting structures of the dentition. Emphasis has traditionally been placed on the deleterious actions of lipid mediators, such as prostanoids and leukotrienes, in propagating the inflammatory response and enhancing tissue destruction. Recently, the emerging understanding of the molecular basis of inflammation has elucidated that return of tissue homeostasis, triggered as part of a normal inflammatory response i.e. resolution of inflammation is an active, agonist-mediated, well-orchestrated phenomenon. The naturally-occurring pro-resolution lipid mediators, lipoxins, resolvins, protectins, maresins etc. have been identified as a novel genus of potent and stereoselective players that counter-regulate excessive acute inflammation and stimulate molecular and cellular events that define resolution. In this Review, we provide an update and overview of newly identified mediators that play pivotal roles in resolution and focus on the emerging appreciation of the endogenous pathways and mediators that control timely resolution which can be exploited as novel drug targets to extend the pharamaceutical armamentarium to combat chronic inflammation, thus controlling periodontal inflammation and the associated systemic inflammatory effects on the body, in general.
authors.affiliation: Baba Farid University of Health Sciences, India. vishakha_grover@rediffmail.com
authors.forename: Vishakha
authors.initials: V
authors.lastname: Grover
authors.forename: Ranjan
authors.initials: R
authors.lastname: Malhotra
authors.forename: Anoop
authors.initials: A
authors.lastname: Kapoor
authors.forename: Jasvinder
authors.initials: J
authors.lastname: Singh
authors.forename: Sonia
authors.initials: S
authors.lastname: Sachdeva
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018957:CD59 Antigens / Q000378:metabolism / Q000627:therapeutic use; D015195:Drug Design; D015525:Fatty Acids, Omega-3 / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D044045:Lipoxins / Q000378:metabolism / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D010518:Periodontitis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D010519:Periodontium / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018957:CD59 Antigens; D015525:Fatty Acids, Omega-3; D018836:Inflammation Mediators; D020024:Leukotriene Antagonists; D044045:Lipoxins; D011448:Prostaglandin Antagonists